FRYL

Across TCGA pan-cancer cohorts, FRYL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FRYL data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher FRYL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FRYL expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

ESCA, STAD, and KIRC are the cancer types where FRYL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.074	0.703	<.001	37	view →
STAD	DFS	Median	II,III,IV	1.000	0.370	.020	29	view →
KIRC	DFS	Median	All	0.127	0.865	<.001	6	view →
PRAD	DFS	Median	All	0.617	0.886	.035	6	view →
SKCM	DFS	Median	All	0.639	0.208	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FRYL–ESCA (OS)

Open the ESCA breakdown →